+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

M

Actively Recruiting

Healthy Volunteer

Researchers are conducting a multi-center clinical study to assess artificial intelligence AI algorithms for measuring heart function and size using echocardiography. The study aims to compare AI measurements with those of physicians at different experience levels, evaluate the accuracy and stability of AI, and explore its use in complex heart conditions like cardiomyopathy, valve disease, and coronary heart disease. The goal is to improve diagnostic consistency and clinical workflows across medical centers. The study involves measuring cardiac chamber size and function in 1600 participants using AI, senior physicians, and intermediate physicians. All measurements are made with Mindray ultrasonic machines. AI and intermediate physician results are completed within one day after data collection, while senior physician results are completed within one month. The study will establish a standardized reference system for AI-assisted echocardiographic measurements and evaluate AIs performance in special cases. Participants will undergo echocardiographic scans with measurements of left and right ventricular size and function, Doppler ultrasound indicators, and valve annulus displacements. Researchers will analyze data to compare AI and physician measurements, assess measurement deviations, and evaluate AIs efficiency in reducing analysis time. The study will run until July 2026, with ongoing data collection and analysis across multiple centers, aiming to promote wider clinical application of AI technology for cardiovascular disease diagnosis.

Age: 18Years - 80YearsAll Genders
37 locations
P

Actively Recruiting

Researchers are studying the safety, tolerability, and effectiveness of elecoglipron alone or combined with dapagliflozin compared to placebo in adults with type 2 diabetes mellitus T2DM who are not well controlled with lifestyle changes or other glucose-lowering medications. This Phase III trial aims to better understand how these treatments impact blood sugar control and other health measures. Participants will be randomly assigned to one of four groups elecoglipron at dose level 1 with dapagliflozin placebo, elecoglipron at dose level 2 with dapagliflozin placebo, elecoglipron at one of the studied doses combined with dapagliflozin, or matching placebos for both drugs. All medications are taken orally once daily. The study lasts 40 weeks, during which participants receive their assigned treatment and are monitored. During the study, participants will undergo regular assessments including measurements of blood sugar control HbA1c, body weight, and blood pressure from baseline to Week 40. Researchers will also track the achievement of specific blood sugar targets, weight loss percentages, and the time before needing additional diabetes medication. Safety and tolerability will be monitored throughout the treatment period. The total participation duration is approximately 40 weeks.

Age: 18Years +All GendersPhase 3
149 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.

Age: 40Years - 80YearsAll GendersPhase 3
305 locations
C

Actively Recruiting

Researchers are investigating the effects of amlodipine alone versus amlodipine combined with folic acid in Chinese adults aged 45 to 74 years who have H-type hypertension, specific MTHFR 677 genotypes CC or CT, elevated plasma homocysteine levels, and low serum folate. This large, multi-center, randomized, double-blind, double-dummy clinical trial aims to evaluate which treatment better reduces the risk of first ischemic stroke over five years. Participants are first screened and then enter a 2 to 4 week run-in period where they take amlodipine to assess tolerance and compliance. Afterward, eligible participants are randomized by genotype into two groups one receiving amlodipine 5mg daily with a placebo, and the other receiving amlodipine 5mg combined with 0.8mg folic acid daily with a placebo. Other blood pressure medications may be added as needed to reach target blood pressure goals. Follow-up visits occur every three months during the five-year treatment period with medication provided at each visit. Throughout the study, participants undergo interviews, clinical evaluations, and laboratory tests including genetic and blood analyses. Researchers monitor adherence, blood pressure, and cardiovascular health. The main outcome measured is the occurrence of first ischemic stroke by the end of five years. Secondary outcomes include other cardiovascular events and kidney function. Two interim analyses will be conducted during the study to assess progress and safety.

Age: 45Years - 74YearsAll GendersPhase 4
20 locations
C

Actively Recruiting

Researchers are evaluating the effects of different amlodipine-based treatments on the risk of first ischemic stroke in Chinese adults aged 45 to 74 years with hypertension and the MTHFR 677 TT genotype. This large, multi-center, randomized, double-blind, triple-dummy controlled trial aims to compare amlodipine alone, amlodipine combined with folic acid, and amlodipine combined with folic acid plus 5-methyltetrahydrofolate over a 5-year period. The study focuses on preventing ischemic stroke as the primary outcome. Participants first undergo a screening period to confirm eligibility through interviews, clinical evaluations, and lab tests. Those who qualify enter a 2 to 4 week run-in phase with daily amlodipine to check treatment tolerance and compliance. Eligible participants are then randomly assigned to one of three daily oral treatment groups amlodipine alone, amlodipine folic acid, or amlodipine folic acid plus 5-MTHF. Additional antihypertensive medications may be added as needed to control blood pressure. Participants are followed every 3 months for drug distribution and monitoring. Throughout the study, participants will have regular clinical visits, interviews, and biological sample collections to monitor health and treatment effects. Researchers will track the incidence of first ischemic stroke and other cardiovascular and kidney outcomes over five years. Safety and treatment adherence are carefully observed, with two planned interim analyses during the trial. Total participation spans from initial screening through five years of treatment and follow-up.

Age: 45Years - 74YearsAll GendersPhase 4
20 locations
E

Actively Recruiting

Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.

Age: 18Years +All GendersPhase 3
119 locations
I

Actively Recruiting

Researchers are evaluating intravenous recombinant human Prourokinase rhPro-UK in patients who have suffered an acute ischemic stroke caused by large vessel occlusion occurring 4.5 to 24 hours after the last known well time. This phase III, randomized, double-blind, placebo-controlled trial aims to determine if rhPro-UK improves blood flow before thrombectomy and enhances functional outcomes after 90 days, while also assessing potential risks like symptomatic brain bleeding and mortality. Participants will be randomly assigned to receive either an intravenous dose of rhPro-UK or a matching placebo. The rhPro-UK dose consists of 15 mg given as an intravenous push within 5 minutes, followed by a continuous infusion of 20 mg over 30 minutes. All participants will also undergo endovascular thrombectomy. The study includes a control group receiving placebo plus thrombectomy to compare outcomes. Throughout the study, participants will have neuroimaging scans such as CT, CTA, MRI, or MRA at 24 hours after treatment to evaluate reperfusion. Stroke severity will be assessed using the NIH Stroke Scale at 5 to 7 days or hospital discharge, and functional independence will be measured by the modified Rankin Scale at 90 days. Safety monitoring focuses on brain hemorrhage and mortality events. The trial is designed with blinded outcome assessment and independent safety oversight, lasting up to 90 days for primary outcomes.

Age: 18Years +All GendersPhase 3
10 locations
R

Actively Recruiting

Researchers are evaluating the efficacy and safety of RC1416 injection in patients with moderate to severe chronic obstructive pulmonary disease COPD. This phase II, multicenter, randomized, double-blind, placebo-controlled study aims to assess important clinical outcomes such as the annual rate of moderate or severe COPD exacerbations and changes in lung function measured by forced expiratory volume in 1 second FEV1 over a 52-week treatment period. Participants will receive either RC1416 injection or a placebo by subcutaneous injection once every two weeks for a total treatment duration of 52 weeks. The study also evaluates changes in biomarkers including fractional exhaled nitric oxide FeNO, total immunoglobulin E IgE, eosinophil count, and thymus and activation-regulated chemokine TARC from baseline during treatment. Throughout the study, participants will be closely monitored with assessments focusing on safety, tolerability, pharmacokinetics, immunogenicity, and biomarkers predictive of efficacy. These evaluations occur during the 52-week treatment period, allowing researchers to comprehensively analyze both clinical and biological responses. The total participation duration aligns with the full year of treatment and follow-up assessments.

Age: 40Years - 85YearsAll GendersPhase 2
46 locations
O

Actively Recruiting

Healthy Volunteer

Researchers are evaluating pulsatile electrical impedance tomography EIT as a noninvasive, bedside, radiation-free method to diagnose and monitor acute pulmonary embolism, a serious type of venous thromboembolism. The study includes both retrospective and prospective phases to compare EIT parameters with CT pulmonary angiography and clinical indicators. This observational research aims to assess whether EIT can aid in diagnosis, risk stratification, and dynamic treatment monitoring for patients with pulmonary embolism. The study uses pulsatile EIT to measure ventilation-perfusion matching index, dead-space ventilation index, and intrapulmonary shunt index. In the retrospective phase, existing clinical and EIT data from patients confirmed with pulmonary embolism and healthy controls are collected and compared. The prospective phase enrolls newly diagnosed patients and healthy volunteers, performing EIT examinations alongside routine clinical evaluations and follow-up. Serial EIT measurements may track changes during treatment and recovery. No study treatments are assigned clinical care follows standard practice. Participants will undergo EIT examinations and routine clinical assessments including CT pulmonary angiography, D-dimer tests, and echocardiography. Researchers will measure diagnostic accuracy of EIT parameters and their correlation with embolic burden, thrombus location, clinical risk, and patient outcomes. Dynamic changes in EIT readings during treatment and follow-up will also be evaluated. The study spans multiple centers and involves healthy volunteers, with participation lasting through initial diagnosis and follow-up periods as determined by clinical care.

Age: 18Years +All Genders
4 locations
E

Actively Recruiting

Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of TQC2731 injection in adults with severe asthma that is not adequately controlled. The study aims to compare TQC2731 with a placebo to better understand its impact on asthma exacerbations and other clinical outcomes in this population. Participants are randomly assigned in a 11 ratio to receive either TQC2731 injection or placebo via subcutaneous injection every 4 weeks. Treatment cycles last 4 weeks each, with study drug administration continuing from Day 0 up to Week 48. The trial includes two groups one receiving the active drug and the other receiving placebo, both with the same dosing schedule. During the study, participants will be monitored for asthma exacerbations, lung function through forced expiratory volume in 1 second FEV1, asthma control questionnaires, quality of life assessments, symptom diaries, and biomarker changes such as blood eosinophils and immunoglobulin E levels. Safety assessments include monitoring for anti-drug antibodies and neutralizing antibodies. The primary outcome is the annualized incidence of asthma exacerbations from the first day of dosing through 52 weeks. Secondary outcomes and safety follow-up extend up to Week 64.

Age: 18Years - 75YearsAll GendersPhase 3
101 locations